RxDoctor Payments Data

Jamon Pruitt, MD

Interventional Cardiology · Bentonville, ARNPI 1174567812

Payments from drug & device makers

$2,293in general payments, 2019–2025

Across 99 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$298
  • Abiomed$219
  • Novartis$205
  • Boston Scientific$191
  • Cordis US CORP.$158
  • Edwards Lifesciences$151
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,293 in reported general payments places this provider in the 15th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$143,410
Medicare patients
1,079
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$135,484
EntrestoSacubitril/Valsartan60$60,692
XareltoRivaroxaban42$42,242
BrilintaTicagrelor28$19,889
Metoprolol Succinate167$2,225
ClopidogrelClopidogrel Bisulfate233$2,081
Atorvastatin Calcium174$1,581
Digoxin65$1,336
Isosorbide Dinitrate21$1,271
Carvedilol157$1,043
Amiodarone Hcl90$798
Bisoprolol Fumarate22$702
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide45$653
Dilt-XrDiltiazem Hcl13$549
Losartan Potassium74$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$135,484168 claims
NovartisEntresto$205$60,69260 claims
Johnson & JohnsonXarelto$18$42,24242 claims
AstraZenecaBrilinta$105$19,88928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →